{"id":"neofordex","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Immunosuppression-related adverse events"}]},"_chembl":{"chemblId":"CHEMBL1530428","moleculeType":"Small molecule","molecularWeight":"434.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Neofordex selectively activates glucocorticoid receptors to suppress inflammatory and immune responses. By targeting glucocorticoid receptor signaling pathways with improved selectivity, it aims to provide anti-inflammatory benefits while minimizing adverse effects associated with traditional broad-spectrum corticosteroids.","oneSentence":"Neofordex is a selective glucocorticoid receptor agonist that modulates immune and inflammatory responses with reduced systemic side effects compared to conventional corticosteroids.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:49.788Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute graft-versus-host disease (aGVHD)"}]},"trialDetails":[{"nctId":"NCT04968899","phase":"PHASE3","title":"IgIV Plus Prednisone vs High-dose Dexamethasone for ITP","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-04-07","conditions":"Immune Thrombocytopenia (ITP)","enrollment":272}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dexamethasone"],"phase":"phase_3","status":"active","brandName":"Neofordex®","genericName":"Neofordex®","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neofordex is a selective glucocorticoid receptor agonist that modulates immune and inflammatory responses with reduced systemic side effects compared to conventional corticosteroids. Used for Acute graft-versus-host disease (aGVHD).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}